The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1671
ISSUE 1671
March 6, 2023
Issue 1671
- Antiviral Drugs for COVID-19 in Vaccinated Outpatients
- Live Fecal Microbiota (Rebyota) for Prevention of CDI Recurrence
- Ublituximab (Briumvi) for Relapsing Multiple Sclerosis
- Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer
- In Brief: Adstiladrin – A Gene Therapy for Bladder Cancer (online only)
- Mosunetuzumab (Lunsumio) for Follicular Lymphoma (online only)
- In Brief: A New Breast Cancer Indication for Sacituzumab Govitecan (Trodelvy) (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Antiviral Drugs for COVID-19 in Vaccinated Outpatients
March 6, 2023 (Issue: 1671)
Three products are currently available in the US for
treatment of high-risk,1 nonhospitalized adults with
mild to moderate COVID-19: oral ritonavir-boosted
nirmatrelvir (Paxlovid), IV remdesivir (Veklury), and
oral molnupiravir (Lagevrio)....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.